NTL Healthcare (CEO Tae-hee Kim) has unveiled an artificial intelligence (AI) solution for cervical cancer.

 

NTL Healthcare, Korean obstetrics and gynecology specialized company, announced that participated in the largest medical exhibition "KOAMEX 2023" held from June 30th to July 2nd at Daegu EXCO.

 

At this exhibition, NTL unveiled ▲CerviCARE^® AI, an AI diagnostic assistance system for cervical cancer, and Dr.Cervicam^® C20, a cervical magnification imaging and reading system.

 

In addition to product exhibitions, NTL is participating in the "Digital Healthcare Medical Device Demonstration Support Project" overseen by the Korea Health Industry Development Institute and performed by the Daegu-Gyeongbuk Advanced Medical Industry Promotion Foundation, and announced the effectiveness evaluation and research results of CerviCARE^® AI.

 

CerviCARE^® AI is a medical AI diagnostic system for cervical cancer that allows you to check the results within 5 seconds (1) in an outpatient setting. CerviCARE^® AI, which boasts a high accuracy based on big data accumulated by NTL for 27 years, received Class 3 approval for gynecology medical software from the Korea Ministry of Food and Drug Safety in December last year. With the introduction of CerviCARE^® AI, it can be used as a medical diagnostic assistance within university hospitals. Dr.Cervicam^® C20 has the advantage of high resolution and easy mobility, making it suitable for various purposes.

 

In addition, CerviCARE^® AI is proceeding with system exports to various countries, including Brazil, Vietnam, Mongolia, and Costa Rica, after concluding contracts. Along with global services, it is collaborating with medical specialists at domestic university hospitals for multi-institutional research with overseas countries. In particular, it has completed approval from the Thai Food and Drug Administration (TFDA) and is expanding into the Thai market.

 

NTL Healthcare (CEO Tae-hee Kim) said, "The AI cervical cancer analysis system is a system that allows all women, regardless of borders and regions, to receive safe and convenient screening for cervical cancer. In addition to CerviCARE^® AI, we plan to introduce various platforms focusing on gynecology and women's diseases."

 

 

 

Ref: 1) Test Report, Standard Bank, 2023